Review ArticleVascular Cytochrome P450 Enzymes: Physiology and Pathophysiology
Introduction
Cytochrome P450 enzymes are classically linked to detoxification processes in the liver but are also expressed in other cell types, in which they can utilize endogenous substrates to generate intracellular second messengers. This review concentrates on describing the physiological and pathophysiological implications of alterations in the expression and activity of the vascular arachidonic acid epoxygenases.
Section snippets
Cytochrome P450 Enzymes
Cytochrome P450 (CYP) enzymes are membrane-bound, heme-containing terminal oxidases that exist as part of a multienzyme system that includes an flavin adenine dinucleotide/flavin mononucleotide–containing nicotinamide adenine dinucleotide phosphate CYP reductase and cytochrome b5. Although many CYP isozymes can also oxidize numerous endogenous substrates, such as eicosapentaenoic acid, retinoic acid, and linoleic acid, they are often referred to as the third pathway of arachidonic acid
Vasodilatation
Epoxyeicosatrienoic acids are vasodilator eicosanoids, and CYP-derived EETs have been implicated in nitric oxide (NO) and prostacyclin (PGI2)-independent vasodilatation in a number of (but not all) vascular beds, in particular coronary and renal arteries from humans, pigs, cows, dogs, rats, and rabbits (for review, see Michaelis and Fleming 2006). Although it is possible to specifically target CYP enzymes in isolated arteries from experimental animals to demonstrate the importance of
Cytochrome P450 Enzymes and Vascular Disease
Given that the EET/EDHF pathway is assumed to be a backup vasodilator mechanism to ensure vasodilatation in the absence of NO or following a decrease in its bioavailability, it would make sense to look for associations with alterations in the generation and or breakdown of EETs in different cardiovascular diseases.
Cytochrome P450 enzymes and cardiovascular disease are potentially linked at two levels. The first relates to the role of EETs in the regulation of vascular homeostasis (described
What's EETing the Lung?
Admittedly, the literature on this topic was controversial for quite a long time, with EETs being reported to have both vasodilator and vasoconstrictor actions depending on which branch of the pulmonary vascular tree was assessed (Jacobs and Zeldin 2001). However, it now seems that the activation of CYP epoxygenases in the lung potentiates hypoxia-induced pulmonary vasoconstriction and promotes the development of pulmonary hypertension. The molecular mechanisms underlying this effect are
Cytochrome P450 Enzymes and Cancer
Given the evidence linking EETs to angiogenesis, it makes sense to look for similarly strong links to cancer. Several CYP enzymes are expressed at higher levels in cancerous tissue than in noncancerous tissue from the same individuals (Jiang et al. 2005), and high CYP expression/activity has been linked to increased tumor malignancy (Jiang et al. 2007). However, such global statements seem to be dependent on the type of cancer investigated and are generally controversial (Bergheim et al. 2007).
Polymorphisms
Given the anti-inflammatory properties attributed to the EETs, it is tempting to look for a link between gain and loss of function polymorphisms of the CYP epoxygenase and sEH (EPHX2) genes and vascular disease.
Outlook
Because the first proposal that CYP-derived metabolites of arachidonic acid may be linked to vascular smooth muscle hyperpolarization and relaxation, it has become clear that the arachidonic acid epoxides (5,6-, 8,9-, 11,12-, and 14,15-EET) are important intracellular signaling molecules that modulate much more than membrane potential. The vasodilator and anti-inflammatory actions of EETs mean that therapies that increase their generation or prevent their degradation may prove beneficial in the
Acknowledgments
The author acknowledges the work of the many groups whose work has not been possible to cite here because of space limitations. Work performed in the authors' own laboratory was supported by the Deutsche Forschungsgemeinschaft (SFB-TR 23, A6 and GRK 757).
References (57)
- et al.
EDHF: bringing the concepts together
Trends Pharmacol Sci
(2002) - et al.
The prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension
Am J Hypertens
(2005) - et al.
TRP channels in hypertension
Biochim Biophys Acta (BBA)—Molecular Basis of Disease
(2007) Cytochrome P450 2C is an EDHF synthase in coronary arteries
Trends Cardiovasc Med
(2000)- et al.
Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system
Trends Pharmacol Sci
(2007) - et al.
Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction
Atherosclerosis
(2007) - et al.
From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: epoxyeicosatrienoic acids (EETs) and cell signaling
Pharmacol Ther
(2006) - et al.
Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients
Biochem Biophys Res Commun
(2005) - et al.
Nitric oxide- and EDHF-mediated arteriolar tone in uremia is unaffected by selective inhibition of vascular cytochrome P450 2C9
Kidney Int
(2005) - et al.
Differential regulation of soluble epoxide hydrolase by clofibrate and sexual hormones in the liver and kidneys of mice
Biochem Pharmacol
(1995)
Identification and functional characterization of human soluble epoxide hydrolase genetic polymorphisms
J Biol Chem
Cytochrome P450 epoxygenase CYP2J2 and the risk of coronary artery disease
Trends Cardiovasc Med
Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking
Atherosclerosis
CYP2C9 allele variants in Chinese hypertension patients and healthy controls
Clin Chim Acta
Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo
Proc Natl Acad Sci U S A
Crucial role of NO and endothelium-derived hyperpolarizing factor in human sustained conduit artery flow-mediated dilatation
Hypertension
Evidence for a basal release of a cytochrome-related endothelium-derived hyperpolarizing factor in the radial artery in humans
Am J Physiol Heart Circ Physiol
Cytochrome P450 levels are altered in patients with esophageal squamous-cell carcinoma
World J Gastroenterol
Cytochrome p450 2C (CYP2C) in ischemic heart injury and vascular dysfunction
Can J Physiol Pharmacol
Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation
Proc Natl Acad Sci U S A
Activation of peroxisome proliferator-activated receptor a by substituted urea-derived soluble epoxide hydrolase inhibitors
J Pharmacol Exp Ther
Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease
Circulation
Cytochrome P450 2C9 is involved in flow-dependent vasodilation of peripheral conduit arteries in healthy subjects and in patients with chronic heart failure
Eur J Heart Fail
Cytochrome P450 2C is an EDHF synthase in coronary arteries
Nature
Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries
Circ Res
Epoxyeicosatrienoic acids regulate Trp channel dependent Ca2+ signaling and hyperpolarization in endothelial cells
Arterioscler Thromb Vasc Biol
Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: the Coronary Artery Risk Development in Young Adults (CARDIA) study
Circulation
The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke
Hum Mol Genet
Cited by (92)
Carcinogenesis: Failure of resolution of inflammation?
2021, Pharmacology and TherapeuticsRole of epoxyeicosatrienoic acids in the lung
2020, Prostaglandins and Other Lipid MediatorsCitation Excerpt :Because CYP2C8 has been reported in some cells of the lung, it is plausible that it participates in the modulation of pulmonary vascular and bronchial tone, as well as CYP2J2, which is also implicated in this process [19]. Despite these findings, EETs possess both vasodilator and vasoconstrictor effects in different branches of the pulmonary vascular tree [20–22]. For example, CYP2C activity can generate superoxide anions with vasoconstrictor function [21], and EETs produced by vascular smooth muscle cells could potentiate vasoconstriction that could be linked to the response against hypoxic pulmonary vasoconstriction (HPV) [22,23].
Cytochrome P450 epoxygenases and cancer: A genetic and a molecular perspective
2019, Pharmacology and TherapeuticsEpoxygenase inactivation exacerbates diet and aging-associated metabolic dysfunction resulting from impaired adipogenesis
2018, Molecular MetabolismCitation Excerpt :EETs are metabolized by soluble epoxide hydrolase (sEH) to the corresponding dihydroxyeicosatrienoic acids and sEH inhibition is a commonly used pharmacological approach aimed to increase intracellular EET pools. The previously reported biological effects of EETs are remarkably pleiotropic, ranging from anti-inflammatory and cardioprotective actions [14–16] to a regulatory role in cancer [17], organ/tissue regeneration [18], and embryonic haematopoiesis [19]. EETs are PPARγ ligands [20] and activators of PPARα [21].
Omega-3 fatty acid epoxides produced by PAF-AH2 in mast cells regulate pulmonary vascular remodeling
2022, Nature Communications